Fujino S, Enokibori T, Tezuka N, Asada Y, Inoue S, Kato H, Mori A
Second Department of Surgery, Shiga University of Medical Science, Japan.
Eur J Cancer. 1996 Nov;32A(12):2070-4. doi: 10.1016/s0959-8049(96)00243-2.
Epidermal growth factor receptor (EGFR) was measured using a competitive radioligand binding assay in membrane preparations from 74 primary human non-small cell lung cancer (NSCLC) tissues and 20 pathologically normal peripheral lung tissues. The mean EGFR level in tumours was 30.38 fmol/mg (+/-41.95 S.D.) of membrane protein (mg.p), significantly higher (P = 0.00016) than in normal tissues (mean, 10.26 +/- 10.02 fmol/mg.p). The mean EGFR concentration was also significantly higher in pathological stage IV tissue than in stages I (P = 0.049) and II (P = 0.040), and the mean EGFR concentration was significantly higher in cases with mediastinal involvement than in cases without it (P = 0.029). The mean EGFR level was higher in DNA aneuploid and multiploid cases than in DNA diploid cases, but there was no significant difference. No significant relationships were found to exist between receptor concentrations and pathological tumour size or histological type, or patient gender or age. From the above findings, a possible prognostic role for EGFR in primary NSCLC should be investigated.
采用竞争性放射性配体结合分析法，对74例原发性人非小细胞肺癌（NSCLC）组织和20例病理正常的外周肺组织的膜制剂中的表皮生长因子受体（EGFR）进行了检测。肿瘤中EGFR的平均水平为30.38 fmol/mg膜蛋白（mg.p）（标准差为±41.95），显著高于正常组织（平均值为10.26±10.02 fmol/mg.p）（P = 0.00016）。IV期病理组织中EGFR的平均浓度也显著高于I期（P = 0.049）和II期（P = 0.040），有纵隔受累的病例中EGFR的平均浓度显著高于无纵隔受累的病例（P = 0.029）。DNA非整倍体和多倍体病例中的EGFR平均水平高于DNA二倍体病例，但无显著差异。未发现受体浓度与病理肿瘤大小、组织学类型、患者性别或年龄之间存在显著关系。根据上述发现，应研究EGFR在原发性NSCLC中的可能预后作用。
